Teijin Limited

Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Nagasaki University

Japanese Foundation for Cancer Research

Mercian Corporation

Iwate Medical University

Hiro International Co., Ltd.

Takao Yamori

Kiyoshi Okamoto

Naoki Tsuchiya

Mitsuo Nagai

Yoshihiko Kotake

Jun Niijima

Naoki Hase

Takashi Nakashima

Satoshi Yamamoto

Toshio Tsuchida

Susumu Takeuchi

Takashi Tsuruo

Masashi Yoshida

Kazuyuki Dobashi

Takumi Takeyasu

Yoshiharu Mizui

Toshimitsu Uenaka

Tomohiro Sameshima

Naoto Kawamura

Susumu Takeda

Masanori Fujita

Naoki Asai

Motoko Matsufuji

Takashi Sakai

Tomonari Yamada

Akifumi Okuda

Masao Iwata

Hiroyasu Ishii

Koji Norihisa

Keisuke Komeda

Kumiko Kishi

Yoshihiro Mimaki

Yutaka Sashida

Minpei Kuroda

Yoshimasa Uehara

Ryosuke Kobayashi

Hiroaki Kando

Kosuke Nosaka

Masatomo Iwao

Tsutomu Fukuda

Naoyuki Nishiya

Yusuke Oku

Fumito Ishibashi

Shingo Dan

Provided is a compound having a tyrosine kinase inhibitory activity specific to C797S resistant mutant EGFR (particularly C797S tertiary-resistant mutant EGFR) and is useful as a C797S resistant mutant EGFR (particularly C797S mutant tertiary-resistant EGFR) specific tyrosine kinase inhibitor, an agent for preventing and/or treating non-small cell lung cancer with resistance mutant EGFR and the like, and the like.

Fourth-generation EGFR tyrosine kinase inhibitor

The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution ofsp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it. 

Bioactive substance

There are provided novel compounds that have been extracted and isolated from a plant belonging to the family Compositae. Compounds represented by general formula (I): wherein Rrepresents hydroxyl and Rrepresents methoxy.

Compound and pharmaceutical composition

The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution ofsp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it

Physiologically active substances

The present invention relates to an anthranilic acid derivative expressed by the following formula (1) or the following formula (2), or its pharmacologically permissible salt or solvate.&#x2003;

Anthranilic acid derivative

The present invention relates to an anthranilic acid derivative expressed by the following formula (1) or the following formula (2), or its pharmacologically permissible salt or solvate.

Anthranilic acid derivatives

Growing community of inventors

Tokyo, Japan

Takao Yamori